Susquehanna International Group
AUPH icon

Susquehanna International Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Susquehanna International Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$601K Buy
40,537
+15,153
+60% +$221K ﹤0.01% 9198
2025
Q4 		$405K Buy
+25,384
New +$360K ﹤0.01% 9266
2025
Q3 		– Sell
-181,783
Closed -$1.99M – 12348
2025
Q2 		$1.54M Buy
181,783
+18,710
+11% +$150K ﹤0.01% 6377
2025
Q1 		$1.31M Sell
163,073
-100,457
-38% -$814K ﹤0.01% 6568
2024
Q4 		$2.37M Buy
263,530
+199,309
+310% +$1.63M ﹤0.01% 4927
2024
Q3 		$471K Sell
64,221
-299,546
-82% -$1.86M ﹤0.01% 8598
2024
Q2 		$2.08M Buy
363,767
+26,010
+8% +$137K ﹤0.01% 5032
2024
Q1 		$1.69M Sell
337,757
-694,847
-67% -$4.71M ﹤0.01% 5724
2023
Q4 		$9.28M Buy
1,032,604
+424,708
+70% +$3.5M ﹤0.01% 2731
2023
Q3 		$4.72M Sell
607,896
-196,590
-24% -$1.92M ﹤0.01% 3629
2023
Q2 		$7.79M Sell
804,486
-253,151
-24% -$2.63M ﹤0.01% 2846
2023
Q1 		$11.6M Buy
1,057,637
+375,975
+55% +$3.31M ﹤0.01% 2271
2022
Q4 		$2.94M Sell
681,662
-94,719
-12% -$550K ﹤0.01% 4045
2022
Q3 		$5.84M Sell
776,381
-940,586
-55% -$8.14M ﹤0.01% 2925
2022
Q2 		$17.3M Sell
1,716,967
-206,038
-11% -$2.3M ﹤0.01% 1579
2022
Q1 		$23.8M Sell
1,923,005
-1,469,001
-43% -$22.7M ﹤0.01% 1556
2021
Q4 		$77.6M Sell
3,392,006
-430,821
-11% -$10.2M 0.01% 846
2021
Q3 		$84.6M Buy
3,822,827
+1,406,345
+58% +$22.3M 0.01% 864
2021
Q2 		$31.3M Buy
2,416,482
+1,062,348
+78% +$13.5M ﹤0.01% 1566
2021
Q1 		$17.6M Sell
1,354,134
-732,263
-35% -$10.6M ﹤0.01% 2026
2020
Q4 		$28.9M Buy
2,086,397
+673,219
+48% +$9.8M ﹤0.01% 1398
2020
Q3 		$20.8M Buy
1,413,178
+317,579
+29% +$4.6M ﹤0.01% 1443
2020
Q2 		$17.8M Sell
1,095,599
-2,852
-0.3% -$45.7K ﹤0.01% 1531
2020
Q1 		$15.9M Buy
1,098,451
+236,581
+27% +$4.17M 0.01% 1343
2019
Q4 		$17.5M Buy
861,870
+219,334
+34% +$2.02M 0.01% 1546
2019
Q3 		$3.43M Buy
642,536
+150,231
+31% +$909K ﹤0.01% 3281
2019
Q2 		$3.24M Sell
492,305
-76,857
-14% -$490K ﹤0.01% 3330
2019
Q1 		$3.7M Buy
569,162
+297,328
+109% +$1.97M ﹤0.01% 2843
2018
Q4 		$1.85M Buy
271,834
+142,055
+109% +$819K ﹤0.01% 3634
2018
Q3 		$862K Sell
129,779
-80,742
-38% -$453K ﹤0.01% 5521
2018
Q2 		$1.19M Buy
210,521
+115,493
+122% +$644K ﹤0.01% 4984
2018
Q1 		$493K Sell
95,028
-45,332
-32% -$243K ﹤0.01% 6663
2017
Q4 		$636K Sell
140,360
-167,316
-54% -$929K ﹤0.01% 6155
2017
Q3 		$1.93M Buy
307,676
+52,043
+20% +$328K ﹤0.01% 3981
2017
Q2 		$1.57M Buy
255,633
+71,005
+38% +$478K ﹤0.01% 4346
2017
Q1 		$1.35M Sell
184,628
-709,525
-79% -$3.28M ﹤0.01% 4491
2016
Q4 		$1.88M Buy
+894,153
New +$2.88M ﹤0.01% 4202

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Susquehanna International Group's AUPH Position: Q1 2026 in Review

Susquehanna International Group increased its Aurinia Pharmaceuticals (AUPH) stake by 60% in Q1 2026, buying an estimated $221K and bringing the position to 40,537 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.

Susquehanna International Group first reported a position in AUPH in Q4 2016 and has held it in 37 quarters since. The position peaked at $84.6M in Q3 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Susquehanna International Group held 40,537 shares of Aurinia Pharmaceuticals worth $601K as of Q1 2026.
  • Susquehanna International Group bought 15,153 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $221K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9198 holding.
  • Susquehanna International Group first reported a position in Aurinia Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
  • Susquehanna International Group's Aurinia Pharmaceuticals position peaked at $84.6M in Q3 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.